Tumor microenvironment dynamics in clear-cell renal cell carcinoma Review
| Authors: | Vuong, L.; Kotecha, R. R.; Voss, M. H.; Hakimi, A. A. |
| Review Title: | Tumor microenvironment dynamics in clear-cell renal cell carcinoma |
| Abstract: | Renal cell carcinoma stands out as one of the most immune-infiltrated tumors in pan-cancer comparisons. Features of the tumor microenvironment heavily affect disease biology and may affect responses to systemic therapy. With evolving frontline options in the metastatic setting, several immune checkpoint blockade regimens have emerged as efficacious, and there is growing interest in characterizing features of tumor biology that can reproducibly prognosticate patients and/or predict the likelihood of their deriving therapeutic benefit. Herein, we review pertinent characteristics of the tumor microenvironment with dedicated attention to candidate prognostic and predictive signatures as well as possible targets for future drug development. Significance: Tumor microenvironment features broadly characterizing angiogenesis and inflammatory signatures have shown striking differences in response to immune checkpoint blockade and antiangiogenic agents. Integration of stromal and immune biomarkers may hence produce predictive and prognostic signatures to guide management with existing regimens as well as future drug development. © 2019 American Association for Cancer Research. |
| Keywords: | signal transduction; vasculotropin; protein expression; treatment response; unclassified drug; single nucleotide polymorphism; bevacizumab; sunitinib; nonhuman; ki 67 antigen; cd8+ t lymphocyte; tumor associated leukocyte; cell survival; ipilimumab; cell infiltration; angiogenesis; protein p53; renal cell carcinoma; hypoxia; pazopanib; short survey; immunomodulation; cytotoxic t lymphocyte antigen 4; macrophage; immunosuppressive treatment; immunosurveillance; loss of function mutation; glycolysis; t lymphocyte activation; hemophagocytic syndrome; programmed death 1 receptor; tumor microenvironment; clinical trial (topic); chemokine receptor cxcr4; peptides and proteins; brca1 associated protein 1; tumor immunogenicity; synergistic effect; nivolumab; human; atezolizumab; adp ribosyl cyclase/cyclic adp ribose hydrolase 1; cd206 antigen; csag family member 2 protein; polybromo 1 protein; perk beta catenin signaling |
| Journal Title: | Cancer Discovery |
| Volume: | 9 |
| Issue: | 10 |
| ISSN: | 2159-8274 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2019-10-01 |
| Start Page: | 1349 |
| End Page: | 1357 |
| Language: | English |
| DOI: | 10.1158/2159-8290.Cd-19-0499 |
| PUBMED: | 31527133 |
| PROVIDER: | scopus |
| PMCID: | PMC6774890 |
| DOI/URL: | |
| Notes: | Short Survey -- Export Date: 1 November 2019 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work